News
-
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
MIRA Pharmaceuticals announces progress in clinical development planning for novel oral ketamine analog, emphasizing early efficacy signal detection in humans by 2025. IND filing on schedule for December 2024 with focus on neuropathic pain treatment -
-
COMMUNIQUÉ DE PRESSE
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Immunic presents key Vidofludimus Calcium data at the 40th Congress of ECTRIMS, highlighting its therapeutic potential in Multiple Sclerosis. Immunic, Inc. (Nasdaq: IMUX) showcases findings at the conference in Copenhagen, Denmark -
COMMUNIQUÉ DE PRESSE
Mawson Announces Signing of Arrangement Agreement for The Spin Out of Uranium Assets in Sweden and Announces Shareholder Meeting Date
Mawson Gold Limited announces spin-out of uranium assets in Sweden to SUA Holdings Ltd. under arrangement agreement, subject to shareholder approval and regulatory clearance -
-
-
COMMUNIQUÉ DE PRESSE
Rapport semestriel au 30 juin 2024
-